NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.20% | -61.49% | -79.44% | -3.75% | -14.49% |
| Total Depreciation and Amortization | -3.35% | -5.39% | -35.02% | -47.52% | -56.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -106.68% | 175.77% | 267.83% | -3.44% | -18.00% |
| Change in Net Operating Assets | -331.23% | -256.27% | -22.51% | 296.65% | 42.66% |
| Cash from Operations | -50.34% | -33.85% | -13.60% | -0.37% | -40.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.22% | 0.83% | 69.48% | 193.09% | 176.03% |
| Cash from Investing | -41.22% | 0.83% | 69.48% | 193.09% | 174.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 41.67% | 16.67% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 1,334.02% | 911.61% | 1.36% | -66.44% | -69.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -914.81% | 0.92% | 45.24% | 57.96% | 62.90% |
| Cash from Financing | 1,401.77% | 1,210.15% | 1.39% | -68.38% | -71.28% |
| Foreign Exchange rate Adjustments | -398.42% | 290.03% | 243.86% | -5,020.45% | -234.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 755.53% | 112.27% | -20.21% | -245.63% | -199.91% |